Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

(2023) L.E. Hendriks et al.   ANNALS OF ONCOLOGY

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options

(2023) Georgia Gomatou et al.   Cancers

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study

(2023) Diego F. Chamorro et al.   Targeted Oncology

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

(2022) Sara M. Tolaney et al.   Frontiers in Oncology

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

(2022) Graziana Digiacomo et al.   Frontiers in Oncology

A review on the role of cyclin dependent kinases in cancers

(2022) Soudeh Ghafouri-Fard et al.   Cancer Cell International

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study

(2022) Assya Akli et al.   Targeted Oncology

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells

(2022) Rita Terenziani et al.   Cancers

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

(2021) Komal Jhaveri et al.   Expert Review of Anticancer Therapy

Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes

(2020) Hirotsugu Hino et al.   CANCER SCIENCE

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer

(2020) Beatrice Gini et al.   Journal of Thoracic Disease

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers

(2020) Helena A. Yu et al.   JAMA Oncology

Beyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase Inhibitors

(2020) Misako Nagasaka et al.   Journal of Thoracic Oncology

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

(2020) Silvia La Monica et al.   Cancers

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

(2019) Silvia La Monica et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion

(2019) Silvia La Monica et al.   Targeted Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

(2019) Daniele Cretella et al.   Scientific Reports

The double dealing of cyclin D1

(2019) Guergana Tchakarska et al.   CELL CYCLE

Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis

(2019) Cheng-Wei Chou et al.   Scientific Reports

Overview of current systemic management of EGFR-mutant NSCLC

(2018) W -H Hsu et al.   ANNALS OF ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

(2018) Zachary A. Yochum et al.   ONCOGENE

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

(2017) Collin M Blakely et al.   NATURE GENETICS

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs

(2016) Juhong Jiang et al.   LUNG CANCER

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer

(2016) Ran Zhao et al.   EBioMedicine

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

(2015) C. A. Eberlein et al.   CANCER RESEARCH

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

(2015) Matthew J. Niederst et al.   Nature Communications

Targeting cell cycle regulation in cancer therapy

(2013) Santiago Diaz-Moralli et al.   PHARMACOLOGY & THERAPEUTICS

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification

(2013) Silvia La Monica et al.   PLoS One

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH